Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)

Next Previous
Trial Profile

IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TMB-380 (Primary) ; Vorinostat (Primary) ; Antiretrovirals; Integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms IGHID 11802; VOR-07

Most Recent Events

  • 25 Sep 2021 Results published in the Journal of Infectious Diseases
  • 21 Jul 2021 Results assessing combined impact of the latency reversing agent vorinostat (VOR) and VRC-07-523-LS, a broadly-neutralizing HIV antibody with prolonged half-life, on the HIV reservoir in HIV+ participants on stable antiretroviral therapy (ART). presented at the 11th International AIDS Society Conference on HIV Science
  • 12 Jul 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top